Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company focused on developing innovative therapeutics based on advanced scientific discoveries from prominent research institutions. The company’s lead candidate is a targeted immuno-oncology gene therapy aimed at treating various cancers. In addition to its primary focus, Scopus is also working on new chemical entities to address serious diseases with unmet medical needs, such as systemic sclerosis. Moreover, the company is exploring therapeutics that target the endocannabinoid system, utilizing synthetically produced cannabinoids instead of plant-derived compounds. Key product candidates include CO-sTiRNA, a STAT3 inhibitor gene therapy, and MRI-1867, further expanding its research into potential treatment options.